0251 GMT - Alcidion's new bull reckons that the healthcare software provider is well placed to deliver positive annual earnings, and maybe even a net profit. Bell Potter analyst Thomas Wakim raises his recommendation on the stock to buy from hold, telling clients in a note that a combination of a cost-cutting restructure with the signing of a large-scale patient-record contract has already delivered modestly positive 1H Ebitda. With A$8 million in licensing revenue scheduled to be recognized in 2H, Wakim anticipates a welcome shift in profitability across Alcidion's full-year result. Bell Potter keeps a A$0.11 target price on the stock, which is down 1.25% at A$0.079. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
March 18, 2025 22:51 ET (02:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。